Use of medication for cardiovascular disease during pregnancy

Area of Science:

• Cardiology
• Pharmacology
• Maternal-Fetal Medicine

Background:

• One-third of pregnant women have heart disease and require medication.
• Pregnancy significantly alters drug pharmacokinetics, often necessitating dose changes.
• Fetal well-being is a primary concern for pregnant women with cardiovascular conditions.

Purpose of the Study:

• To review pharmacokinetic changes of cardiovascular disease (CVD) medications during pregnancy.
• To assess the safety of CVD medications for the fetus.
• To discuss implications for maternal treatment and obstetric medication effects.

Main Methods:

• Literature review of pharmacokinetic changes in CVD medications during pregnancy.
• Analysis of drug safety profiles for pregnant women and fetuses.
• Discussion of clinical implications and management strategies.

Main Results:

• Physiological changes in pregnancy alter drug absorption, distribution, metabolism, and excretion.
• Most CVD medications can be used safely, but certain drugs (e.g., high-dose warfarin, ACE inhibitors) require careful consideration.
• Noncompliance with CVD treatment poses risks to both mother and fetus.

Conclusions:

• Understanding pharmacokinetic shifts is crucial for optimizing CVD medication dosages in pregnant patients.
• Careful selection and monitoring of CVD medications ensure maternal and fetal safety.
• Open communication between cardiologists and pregnant patients is essential for treatment adherence and informed decision-making.